Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

568
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
568
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

542
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
542
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

408
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
408
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

667
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
667
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

700
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
700
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Sudden unexpected cardiac death among the young (5 to 40 years) in Switzerland between 2011 and 2019: incidence and autopsy rate.

International journal of legal medicine·2026
Same author

Sudden unexpected cardiac death among the young (5 to 40 years) in Switzerland between 2011 and 2019: incidence and autopsy rate.

International journal of legal medicine·2026
Same author

The Seaport Criteria: A New Histologic Standard to Diagnose Myocarditis.

JACC. Heart failure·2026
Same author

Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.

Nature communications·2026
Same author

Prevalence and Impact of Partial Anomalous Pulmonary Venous Connection in Turner Syndrome.

CJC pediatric and congenital heart disease·2026
Same author

Preserved Function of Endothelial Colony-Forming Cells in Female Rats with Intrauterine Growth Restriction: Protection Against Arterial Hypertension and Arterial Stiffness?

Cells·2026

Related Experiment Video

Updated: Feb 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K

[Multidisciplinary cardiogenetic counselling].

Florence Fellmann1, Xavier Jeanrenaud2, Nicole Sekarski3

  • 1Service de médecine génétique, CHUV, 1011 Lausanne.

Revue Medicale Suisse
|June 23, 2017
PubMed
Summary

Multidisciplinary cardiogenetic consulting provides a comprehensive approach for inherited heart conditions like channelopathies and cardiomyopathies. This collaborative effort aids patients and families in understanding disease causes, consequences, and management.

More Related Videos

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K

Related Experiment Videos

Last Updated: Feb 27, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

4.3K
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
05:53

Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

Published on: June 21, 2018

10.8K
A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K

Area of Science:

  • Cardiology
  • Genetics
  • Clinical Medicine

Background:

  • Channelopathies and hereditary cardiomyopathies are significant causes of sudden cardiac death and heart failure.
  • Genetic mutations underlie many of these conditions, necessitating specialized diagnostic approaches.

Purpose of the Study:

  • To describe the multidisciplinary cardiogenetic consulting model.
  • To highlight the collaborative approach in managing patients with inherited cardiomyopathies and channelopathies.

Main Methods:

  • A multidisciplinary team including geneticists, cardiologists, and genetic counselors collaborates.
  • Genetic testing is utilized to identify mutations in affected individuals (probands) and their families.

Main Results:

  • Genetic mutations are identified in approximately 50% of patients evaluated.
  • The consulting model provides essential information regarding disease etiology, prognosis, and management.

Conclusions:

  • Multidisciplinary cardiogenetic consulting offers a vital framework for diagnosing and managing inherited cardiac conditions.
  • Close collaboration with treating physicians ensures comprehensive patient care and family support.